AGIO News and Press, Agios Pharmaceuticals Inc.

CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, August 1, 2024, at 8:00 a...

2024-06-25 14:07:48 ET More on iShares Russell 2000 ETF: IWM: Small Caps Look Unattractive With Deteriorating Earnings Outlook IWM: Favor Small Caps Over The Technology Sector IWM: Not The Economy For Underdogs (Rating Downgrade) Gap between growth and small-...

2024-06-19 16:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights Improvements in Fatigue and Exercise Capacity in Patients Treated with...

2024-06-12 07:41:46 ET Summary Agios Pharmaceuticals develops therapies for rare diseases with a focus on Pyruvate Kinase activators like Pyrukynd for PK deficiency. AGIO is advancing its pipeline with research on Mitapivat for thalassemia and sickle cell disease, positioning itse...

2024-06-09 16:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the time of the company’s presentation at the Goldman Sachs 45th Annual Global Heal...

Shares of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) traded at a new 52-week high today and are currently trading at $48.34. So far today, approximately 123.55k shares have been exchanged, as compared to an average 30-day volume of 886.54k shares. Agios Pharmaceuticals, Inc., a biopharmaceuti...

A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 17.9% to $0.1179 on volume of 290,472,504 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 7.1% to $0.6248 on volume of 223,394,331 shares GameStop Corporation (GME) rose 21.0% to $28...

2024-06-03 16:00:09 ET Gregory Renza from RBC Capital issued a price target of $53.00 for AGIO on 2024-06-03 14:30:00. The adjusted price target was set to $53.00. At the time of the announcement, AGIO was trading at $44.26. The overall price target consensus is at $44.2...